A clinical indication is the specific medical condition, symptom, or circumstance that justifies using a particular treatment, test, or procedure. When a drug label says it is “indicated for” moderate-to-severe psoriasis, that means regulators reviewed evidence and concluded the drug works well enough for that condition to earn formal approval. The concept sounds straightforward, but indications quietly shape nearly every decision in healthcare, from what your doctor prescribes to whether your insurance pays for it, and even what happens when a treatment is used for something it was never officially approved to treat.
What Makes Something an Approved Indication
Before a drug or medical device can be marketed for a specific condition, it must go through a formal approval process overseen by a regulatory agency. In the United States, that agency is the Food and Drug Administration (FDA); in Europe, it is the European Medicines Agency (EMA). The manufacturer submits clinical trial data showing the product is safe and effective for a defined patient population with a defined condition. That condition, once approved, becomes the product’s indication.
Getting there is neither quick nor cheap. New drugs in the United States take an average of about 12 years from preclinical testing to approval, while medical devices average around 7 years, and the cost of bringing a new drug to market can exceed a billion dollars.1Elsevier / ScienceDirect. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs – Section: Summary A large chunk of that time and money goes toward proving, through controlled trials, that the drug actually works for a specific condition in a specific group of patients. The resulting label language is precise: it names the disease, often specifies severity, and sometimes limits the indication to patients who have failed other treatments first.
An approved indication is not a permanent, universal verdict. It reflects the evidence that was available at the time of approval and the judgment of one particular agency. A drug can gain additional indications later if the manufacturer runs new trials and submits fresh data. It can also lose indications or gain new restrictions if safety problems surface after it reaches the market.
Why the FDA and EMA Sometimes Disagree
You might assume that a drug approved in the United States carries the same indications in Europe, but that is not always the case. When researchers compared FDA and EMA decisions on new drug applications submitted between 2014 and 2016, they found that disagreements in approval decisions and approved indications were driven primarily by the agencies reaching different conclusions about how well the drug worked, sometimes while reviewing the same clinical data.2PubMed Central. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why In some cases the agencies reviewed different datasets entirely because the manufacturer submitted different supporting evidence to each.
Despite international efforts to harmonize how agencies evaluate drugs, meaningful differences persist, especially when regulators face urgent public health situations and must weigh speed against the completeness of available evidence.3PubMed Central. Comparison of drug approvals of the FDA and EMA between 2013 and 2023 For patients and doctors, this means that a treatment considered standard of care in one country may not yet be approved for the same condition somewhere else. Travelers, people seeking second opinions across borders, or patients reading international research can run into confusing situations where a drug’s indication in one market does not match its status in another.
Off-Label Prescribing and Its Risks
A doctor is not legally required to prescribe a drug only for its approved indication. Physicians regularly prescribe medications “off-label,” meaning they use a drug for a condition, age group, or dose that falls outside what the FDA formally approved. This is not inherently reckless. Many off-label uses are well supported by published research and clinical experience, and in certain specialties it is nearly unavoidable. Pediatric medicine is a prime example: because clinical trials historically enrolled adults far more often than children, many drugs that work in kids were never formally studied or approved for them. A review of pediatric clinical guidelines found that the most common type of off-label recommendation involved using a drug in a patient population it was not approved for, accounting for roughly half of all positive off-label recommendations.4PubMed Central. Recommendations on Off-Label Drug Use in Pediatric Guidelines
The practice comes with measurable tradeoffs. A large study of adults found that off-label drug use carried a higher rate of adverse drug events compared to on-label use. But the risk was not uniform. When off-label use was backed by strong scientific evidence, the adverse event rate was only modestly higher and the difference was not statistically significant. When the scientific support was weak, however, the rate climbed substantially, with roughly a 54% higher hazard of adverse events compared to on-label prescribing.5JAMA Internal Medicine. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population The lesson is not that off-label use is dangerous across the board, but that the quality of evidence behind the off-label decision matters enormously.
In pediatric oncology, the stakes of off-label use can be especially stark. One large children’s cancer center found that about 9% of patients receiving targeted anticancer therapies were treated off-label, and that rate increased significantly over the study period. About 15% of those patients had a complete response, but 38% experienced some form of toxicity, and 13% had to stop treatment because of it.6PubMed Central. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center – Section: RESULTS These numbers illustrate the tension at the heart of off-label prescribing: for patients with few alternatives, a drug without a formal indication for their condition may still be the most rational choice, but it comes without the safety net of large controlled trials to quantify the risks in advance.
Indications and Insurance Coverage
If you have ever had a prescription denied by your insurance company, the explanation often traces back to indications. Insurers use approved indications as a gatekeeper. When a drug is prescribed for its FDA-approved indication, coverage is generally straightforward, though prior authorization requirements can still delay things. When a drug is prescribed off-label, the insurer may refuse to cover it entirely or demand extra documentation proving the use is medically necessary.
This creates a real-world problem for patients whose conditions fall outside the label. A drug that works for your disease based on solid clinical evidence may still be denied if the manufacturer never sought formal approval for that specific use. Prior authorization processes, where the doctor must justify the prescription to the insurer before it is filled, add delays that can affect treatment timing. For conditions where prompt treatment matters, those delays carry real consequences. The gap between what is medically reasonable and what is administratively approved is one of the more frustrating features of modern healthcare, and the concept of clinical indication sits right at the center of it.
Contraindications Are the Other Side of the Coin
While an indication tells you when a treatment is appropriate, a contraindication tells you when it is not. The drug label lists conditions or circumstances where the treatment should not be used because the risks outweigh the benefits. Pregnancy, severe liver disease, and known allergy to an ingredient are common examples.
The distinction between absolute and relative contraindications matters more than most people realize. An absolute contraindication means the treatment should never be given under that circumstance. A relative contraindication means the treatment might still be appropriate if the potential benefit is high enough, but extra caution is warranted. The trouble is that drug labels do not always make this distinction clearly. A study examining how physicians and pharmacists interpret contraindication language in official drug product summaries found that clearer differentiation between absolute and relative contraindications could improve how well those warnings are followed. The researchers also noted that the total number of listed contraindications tends to be lower in U.S. drug labels than in their German counterparts, possibly because the U.S. labeling draws a sharper clinical line between what is truly dangerous and what merely calls for extra care.7PubMed Central. Physicians’ and pharmacists’ perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics” – Section: Discussion
Vague contraindication language like “liver disease” without specifying severity can lead to two opposite problems. Doctors may avoid prescribing a treatment for someone who could safely benefit from it, or they may dismiss the warning as overly broad and prescribe it when they should not. Either way, the patient loses. This is why regulatory agencies are increasingly under pressure to make indication and contraindication language more specific and actionable.
How Indications Guide Diagnostic Testing
Indications are not limited to drugs. Every diagnostic test and imaging study has indications too. Ordering an MRI of your knee because you tripped and feel mild soreness is a different clinical situation from ordering the same MRI because you cannot bear weight and your doctor suspects a torn ligament. The clinical indication justifies the test, and when the indication is weak or absent, the test is considered inappropriate.
Measuring whether imaging is ordered appropriately is a growing area of healthcare quality research. A scoping review found that the most common tools used to judge whether a diagnostic imaging order was appropriate were national guidelines and the American College of Radiology Appropriateness Criteria, which match specific clinical scenarios to the imaging study most likely to help.8PubMed Central. Measuring appropriateness of diagnostic imaging: a scoping review – Section: Results Without clear indications, patients get scans they do not need, exposing them to unnecessary radiation, incidental findings that trigger anxiety and more testing, and costs that add up across the healthcare system.
The U.S. government took this seriously enough to mandate that doctors consult a clinical decision support tool before ordering advanced imaging for Medicare patients. Research on this mandate found that as providers gained more experience with the decision support system, the appropriateness of their imaging orders improved. Specifically, the proportion of orders flagged as “usually appropriate” increased with greater exposure to the tool.9PubMed Central. Improved Appropriateness of Advanced Diagnostic Imaging After Implementation of Clinical Decision Support Mechanism In other words, when the system reminded doctors to think about whether the clinical indication truly supported the test, they ordered more wisely over time.
Low-Value Care and the Cost of Weak Indications
When treatments or tests are delivered without a strong clinical indication, the result is what healthcare researchers call “low-value care,” services that cost money and carry risk but deliver little or no benefit to the patient. A study measuring low-value care among Medicare beneficiaries found that services flagged by more sensitive measures affected about 41% of beneficiaries and accounted for roughly 2.7% of total annual spending. Even when using stricter definitions of what counts as low-value, about a quarter of beneficiaries received at least one such service.10PubMed Central. Measuring Low-Value Care in Medicare – Section: Results
These numbers might sound small in percentage terms, but when applied to a program the size of Medicare, they translate to billions of dollars. More importantly, low-value care is not just a financial problem. An unnecessary surgery carries surgical risk. An unneeded antibiotic contributes to drug resistance. A redundant blood test still involves a needle and a bill. The clinical indication is the first checkpoint that is supposed to prevent all of this. When it is skipped, ignored, or poorly defined, the downstream consequences ripple through both the patient’s experience and the broader system.
Clinical Guidelines and How Recommendations Get Their Strength
Clinical indications do not exist in a vacuum. They are shaped by clinical practice guidelines, which synthesize evidence and tell doctors what to do for a given condition. The strength of a guideline recommendation depends on how confident the authors are in the underlying evidence. Most modern guidelines use a system called GRADE, which evaluates the certainty of available evidence and then factors in the balance of benefits versus harms, patient preferences, and resource use to produce either a strong or a conditional recommendation.11PubMed. Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation)
A strong recommendation means the evidence clearly favors one option over another, and it should apply to most patients. A conditional recommendation means the best choice depends on the individual situation, because the evidence is uncertain, the benefits and risks are closely balanced, or patient preferences vary. Higher-certainty evidence supports stronger recommendations, while lower-certainty evidence leads to more cautious, conditional ones.12Clinical Epidemiology and Global Health. Introduction to the GRADE tool for rating certainty in evidence and recommendations – Section: 6. Linking evidence certainty to recommendation strength
For patients, this matters because not every recommendation your doctor follows carries the same weight. Some treatments have robust evidence behind their indicated use. Others are recommended conditionally, meaning “this is probably a reasonable choice, but we are not certain.” Understanding the difference can help you ask better questions when a treatment is suggested, especially when you are weighing side effects against uncertain benefits.
Decision Support Tools in the Clinic
Modern electronic health records increasingly build indication-checking directly into the prescribing process. When a doctor enters an order, the system can flag potential problems: a drug prescribed for a condition it is contraindicated in, a dose inappropriate for a patient with kidney problems, a medication that interacts dangerously with something the patient already takes, or a drug that should not be used during pregnancy. These clinical decision support systems check the prescribed drug against the patient’s specific clinical picture, essentially verifying that the indication and contraindication logic holds.13PubMed Central. Medication-related clinical decision support in computerized provider order entry systems: a review
The technology is imperfect. If the system fires too many alerts, doctors start ignoring them, a well-documented problem called “alert fatigue.” And if contraindication language in the underlying drug databases is vague, the alerts can be overly broad, flagging cases that do not actually warrant concern. Still, these tools represent one of the most concrete ways that clinical indications translate from paper labels into real-time patient safety.
Tissue-Agnostic Indications in Cancer Treatment
One of the most striking recent shifts in how indications work has come from oncology. Traditionally, cancer drugs were approved for cancers defined by where they started: lung cancer, breast cancer, colon cancer. The indication was tied to the organ. In the past several years, regulators have begun approving drugs based not on where the tumor is, but on what genetic mutation drives it. These are called tissue-agnostic indications, and they represent a fundamentally different way of thinking about what a treatment is “for.”14PubMed. The evolving landscape of tissue-agnostic therapies in precision oncology
If a patient’s tumor carries a specific genetic change, the drug may be indicated regardless of whether the cancer started in the lung, the colon, the thyroid, or somewhere else entirely. This approach has produced real results for patients with rare mutations who previously had no approved options. But it also complicates the traditional indication framework. Instead of a neat “Drug X is indicated for Disease Y,” the label describes a molecular target that could appear in dozens of different cancers. Insurance systems, clinical guidelines, and hospital formularies designed around organ-based cancer categories have had to adapt.
Why Health Literacy Changes the Equation
All of this matters only if patients and providers actually understand what indications and contraindications mean in practice. Health literacy, a person’s ability to find, understand, and use health information, plays a surprisingly large role. A study of hypertensive patients found that among those with inadequate health literacy, only about a third adhered to their prescribed medication, compared to roughly two-thirds of those with adequate health literacy.15Journal of Health and Rehabilitation Research. Assessment of Medication Adherence and Its Association with Health Literacy Among Hypertensive Patients
If you do not understand why a drug was prescribed for your condition, you are less likely to take it consistently. If you do not understand the contraindication warnings, you may combine medications in ways that cause harm. And if your doctor prescribes something off-label without explaining why, you might look up the drug, see that your condition is not listed, and stop taking it out of confusion or mistrust. Clear communication about what a drug is indicated for and why your doctor chose it for your situation is one of the simplest interventions available, and one of the most commonly neglected.
When AI Products Blur the Lines
The concept of clinical indication is not limited to drugs and traditional medical devices. As artificial intelligence tools enter clinical practice, particularly in fields like radiology, the question of what an AI product is “indicated for” has become surprisingly murky. Regulators require manufacturers to provide an intended use statement, the AI equivalent of an indication. But a review of 139 commercially available AI products in radiology found that most intended use statements were incomplete. The majority mentioned three or fewer of the six recommended components, and only seven products mentioned all six. Critically, the intended patient population was specified in only about a fifth of cases, and the intended clinical environment was mentioned even less often. In 13 cases, disclaimers within the product documentation actually contradicted the claims made in the intended use statement itself.16Insights Imaging. How AI should be used in radiology: assessing ambiguity and completeness of intended use statements of commercial AI products – Section: RESULTS
This is a problem because the same AI tool might perform differently in a pediatric emergency department than in an outpatient imaging center for elderly patients. Without a clear indication specifying who the tool is meant for and under what conditions, clinicians are left guessing, and patients may be affected by a technology that was never validated for their particular situation. As AI becomes more common in medicine, the rigor we apply to drug and device indications will need to extend to algorithms too.